MX2022004738A - Compuestos superfinos y su produccion. - Google Patents

Compuestos superfinos y su produccion.

Info

Publication number
MX2022004738A
MX2022004738A MX2022004738A MX2022004738A MX2022004738A MX 2022004738 A MX2022004738 A MX 2022004738A MX 2022004738 A MX2022004738 A MX 2022004738A MX 2022004738 A MX2022004738 A MX 2022004738A MX 2022004738 A MX2022004738 A MX 2022004738A
Authority
MX
Mexico
Prior art keywords
production
superfine
compounds
inhalable
purity
Prior art date
Application number
MX2022004738A
Other languages
English (en)
Inventor
H Matthew Jackson
Jinhee Oh
Julian Bryson
Original Assignee
Esolate Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esolate Ltd filed Critical Esolate Ltd
Publication of MX2022004738A publication Critical patent/MX2022004738A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/50—Polysaccharides, gums
    • A23V2250/51—Polysaccharide
    • A23V2250/5112—Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Alcoholic Beverages (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seeds, Soups, And Other Foods (AREA)
  • Cosmetics (AREA)
  • Confectionery (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Tea And Coffee (AREA)

Abstract

La presente invención proporciona ingredientes activos farmacéuticos ultrafinos, comestibles, inhalables, solubles o bebibles, estables de grado farmacéutico, altamente biodisponibles, que tienen una pureza de 99 %, y métodos para su producción.
MX2022004738A 2019-10-21 2020-10-21 Compuestos superfinos y su produccion. MX2022004738A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962923726P 2019-10-21 2019-10-21
US201962929455P 2019-11-01 2019-11-01
PCT/US2020/056731 WO2021081140A1 (en) 2019-10-21 2020-10-21 Superfine compounds and production thereof

Publications (1)

Publication Number Publication Date
MX2022004738A true MX2022004738A (es) 2022-08-04

Family

ID=75620236

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022004735A MX2022004735A (es) 2019-10-21 2020-10-21 Composiciones que comprenden compuestos superfinos y su produccion.
MX2022004738A MX2022004738A (es) 2019-10-21 2020-10-21 Compuestos superfinos y su produccion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022004735A MX2022004735A (es) 2019-10-21 2020-10-21 Composiciones que comprenden compuestos superfinos y su produccion.

Country Status (11)

Country Link
US (1) US20220387339A1 (es)
EP (2) EP4048243A1 (es)
JP (2) JP7444995B2 (es)
KR (2) KR20220084304A (es)
CN (2) CN114630658A (es)
AU (2) AU2020370165A1 (es)
BR (2) BR112022007605A2 (es)
CA (2) CA3158416C (es)
IL (2) IL292404A (es)
MX (2) MX2022004735A (es)
WO (2) WO2021081140A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014605A (es) 2020-05-19 2022-12-16 Cybin Irl Ltd Derivados de triptamina deuterada y metodos de uso.
WO2023053090A1 (en) * 2021-10-01 2023-04-06 Optimi Health Corp. Extraction technique
WO2023161645A2 (en) * 2022-02-24 2023-08-31 Grow Biotech Plc Pharmaceutical compositions for vaporization and inhalation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
JP2003532757A (ja) * 2000-05-11 2003-11-05 イーストマン ケミカル カンパニー アシル化シクロデキストリン：ゲスト分子包接錯体
FR2815540B1 (fr) 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
WO2003000192A2 (en) * 2001-06-22 2003-01-03 Raveendran Poovathinthodiyil Renewable, carbohydrate based co2-philes
FI113340B (fi) * 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
FI20020333A0 (fi) * 2002-02-20 2002-02-20 Tomi Jaervinen Metyloidun syklodekstriinin uudet kompleksit
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
TWI369203B (en) * 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
ES2683851T3 (es) 2006-10-06 2018-09-28 Newsouth Innovations Pty Limited Formación de partículas
FR2914187B1 (fr) 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
KR101701203B1 (ko) * 2014-10-16 2017-02-01 부경대학교 산학협력단 초임계이산화탄소를 이용한 퍼아세틸레이티드 사이클로덱스트린 및 약물의 포접체 초미립자, 이의 제조방법 및 이의 용도
US9398974B1 (en) * 2015-02-10 2016-07-26 Eddy H. delRio Bruxism sensor
JP6953414B2 (ja) * 2016-01-20 2021-10-27 フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法
WO2017223519A1 (en) * 2016-06-24 2017-12-28 Cool Clean Technologies, Llc Liquid carbon dioxide botanical extraction system
NL2018190B1 (en) * 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
US9956498B1 (en) * 2017-01-19 2018-05-01 Metamorphic Alchemy & Distillations, Inc. Method for removing contaminants from cannabinoid distillates
EA202090890A1 (ru) * 2017-10-05 2020-09-03 Ресептор Холдингз, Инк. Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия
CN109985042A (zh) * 2017-12-29 2019-07-09 汉义生物科技（北京）有限公司 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用
US10851077B2 (en) * 2018-02-07 2020-12-01 World Class Extractions Inc. Method for extracting compositions from plants
CN110123876A (zh) * 2019-05-30 2019-08-16 汉义生物科技（北京）有限公司 一种含有非精神活性大麻素的包合物及其制备方法

Also Published As

Publication number Publication date
BR112022007601A2 (pt) 2022-10-04
KR20220084304A (ko) 2022-06-21
WO2021081140A1 (en) 2021-04-29
CN115003288A (zh) 2022-09-02
CN114630658A (zh) 2022-06-14
AU2020370165A1 (en) 2022-04-21
BR112022007605A2 (pt) 2022-10-04
IL292377B2 (en) 2023-11-01
EP4048242A1 (en) 2022-08-31
JP2022545986A (ja) 2022-11-01
EP4048242A4 (en) 2024-05-22
IL292404A (en) 2022-06-01
CA3158416A1 (en) 2021-04-29
AU2020370166A1 (en) 2022-04-21
MX2022004735A (es) 2022-08-04
JP7444995B2 (ja) 2024-03-06
JP2022554420A (ja) 2022-12-28
WO2021081138A1 (en) 2021-04-29
CA3158415A1 (en) 2021-04-29
KR20220110730A (ko) 2022-08-09
AU2020370166B2 (en) 2022-05-19
CA3158416C (en) 2023-12-19
EP4048243A1 (en) 2022-08-31
US20220387339A1 (en) 2022-12-08
IL292377B1 (en) 2023-07-01
IL292377A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2022004738A (es) Compuestos superfinos y su produccion.
MX2020002271A (es) Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
PH12020550341A1 (en) Niraparib formulations
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
WO2017177004A8 (en) Tertiary amides and method of use
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2015001917A (es) Composiciones farmaceuticas de memantina.
MX2022000372A (es) Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbon il)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il ]-benzamida.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MX2021014680A (es) Derivado de benzotriazol.
PH12017501829A1 (en) Pharmaceutical formulations
SA519410097B1 (ar) P2x7 مشتقات رباعي هيدروكوينولين كمعارضات مستقبل
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
MD4615C1 (ro) Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine
NZ741553A (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
PH12016501205B1 (en) Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency
WO2017021974A3 (en) NOVEL SYNERGISTIC COMPOSITION OF LECITHIN AND LYSOLECHINE TO IMPROVE BIOAVAILABILITY AND SOLUBILITY OF HYDROPHOBIC COMPOUNDS AND EXTRACTS
EP4342542A3 (en) Combination of regorafenib and nivolumab for treating cancer
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
MY196333A (en) Intranasal Composition Comprising Betahistine
PH12017501736A1 (en) Indole derivatives